Contingency Management: The Most Effective Meth Treatment Almost Nobody Offers

There are no FDA-approved medications for methamphetamine use disorder. Not one. For opioid use disorder there is methadone, buprenorphine and naltrexone; for stimulants, the pharmacy has nothing to offer.

What does work is a behavioural treatment that sounds almost too simple: pay people, in small amounts, for verified negative drug tests. It is called contingency management, and it has more evidence behind it than any other treatment for stimulant use disorder.

How it works

A person in treatment provides urine samples on a schedule — typically two or three times a week. Each negative test earns an incentive: a voucher, a gift card, or a draw from a prize bowl. The value usually escalates with each consecutive negative test and resets after a positive one.

The mechanism is not bribery. Stimulant use disorder blunts the brain’s response to ordinary rewards, and the natural payoffs of abstinence — health, relationships, work — arrive months later, which is precisely the wrong timescale for a reward system that takes a year or more to recover. Contingency management supplies an immediate, concrete, reliable reward while the internal one is offline.

The $75 problem, and what changed in 2025

This is the single most useful thing to know when evaluating a programme. A provider still designing around the old $75 ceiling is delivering a version of contingency management the research predicts will underperform. It is a fair question to ask them directly.

What the evidence shows

• Contingency management is considered a primary and potentially life-saving intervention for stimulant use disorder, in the absence of any approved medication
• More than 4 million people in the US meet diagnostic criteria for a stimulant use disorder
• It is equally effective for people who use stimulants and opioids concurrently — it combines with medication for opioid use disorder rather than competing with it
• Benefits are strongest while the programme runs; sustaining them afterwards requires the rest of a treatment plan

The objection, and the answer

“Paying people not to use drugs” attracts more moral objection than any other evidence-based treatment in addiction medicine. It is worth being direct about it: we do not object to paying for insulin or for physiotherapy. The objection is not really about cost-effectiveness — incentives are cheap next to an emergency admission — it is about whether people with addiction deserve to be helped in a way that feels like reward.

The counter-argument is simply the outcome data. For a condition with no approved medication, declining the most effective available treatment on the grounds that it feels wrong is a choice with consequences.

Finding a programme

Contingency management is still unevenly available, though that is changing as more state Medicaid programmes cover it. Questions worth asking:

1. Do you offer contingency management for stimulant use disorder?
2. What is the incentive schedule, and does it escalate with consecutive negative tests?
3. What is the maximum annual value? (If the answer is $75, ask whether they have updated to the 2025 guidance.)
4. How long does the programme run, and what happens when it ends?
5. Is it combined with counselling, and with medication if opioids are also involved?

California, Washington, Montana and a growing number of other states have Medicaid-supported programmes. FindTreatment.gov lets you filter by treatment approach.

Sources

• SAMHSA. Contingency Management for Stimulant Use Disorder — Advisory (PEP24-06-001).
• SAMHSA guidance update raising the annual incentive limit to $750 per patient, 8 January 2025.
• Congressional Research Service. Contingency Management for Substance Use Disorders.